Obagi Medical Unveils Pivotal Study Data on Hyaluronic Acid Filler at ASDS Meeting
Waldencast plc presented new clinical data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 ASDS Annual Meeting. The study showed Obagi® saypha® ChIQ™ is non-inferior to Juvéderm Voluma® XC for midface volume restoration and nasolabial fold improvement, with high patient satisfaction and safety. Interim results for Obagi Nu-Cil® BioStim™ Scalp Serum indicated improvements in scalp health and hair appearance at three months.
Waldencast plc announced new clinical data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery (ASDS) Annual Meeting, which took place from November 13-16, 2025, in Chicago, Illinois. The pivotal study compared the effectiveness and safety of Obagi® saypha® ChIQ™ and Juvéderm Voluma® XC for midface volume restoration and nasolabial fold improvement. Results demonstrated non-inferiority of Obagi® saypha® ChIQ™, with high patient satisfaction and robust safety across diverse skin types. Interim results from an ongoing study of Obagi Nu-Cil® BioStim™ Scalp Serum showed improvements in scalp health and hair appearance at three months. These results were presented at the recent ASDS meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waldencast plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576614-en) on November 16, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
